Clinical Trials
17 trialsNCT05053100 2025-05-02
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study
Mayo Clinic
Completed
NCT02744092 2023-10-03
CANVAS
Alliance Foundation Trials, LLC.
Phase NA Completed
NCT03115541 2021-02-24
Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection
McMaster University
Completed
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT03099031 2019-12-16
PREDICARE
LEO Pharma
Completed
NCT02073682 2019-03-06
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
Phase 3 Completed
NCT02334007 2018-09-18
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
McMaster University
Phase 1/2 Completed
NCT01524653 2018-07-10
DISOLVE
University of Vermont
Phase 2 Completed
NCT01444612 2017-05-16
Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
GlaxoSmithKline
Completed
NCT01602445 2017-05-11
REMARK
Ottawa Hospital Research Institute
Completed
NCT00966277 2016-12-12
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 4 Completed
NCT00773448 2015-07-07
SOME
Ottawa Hospital Research Institute
Phase NA Completed
NCT00660205 2012-03-26
GIVTE
University of Aarhus
Completed
NCT00219973 2010-04-28
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
Rovi Pharmaceuticals Laboratories
Phase 3 Completed
NCT00456196 2009-07-13
Epidemiology of Venous Thromboembolism
Brigham and Women's Hospital
Completed
NCT00409136 2009-02-02
Multi-Center Human Alert Trial to Prevent DVT and PE
Brigham and Women's Hospital
Completed
NCT00135876 2007-04-27
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
Ontario Clinical Oncology Group (OCOG)
Phase 3 Completed